Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713090 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4712621 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL11911728 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4759967 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520900 | 0.77 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL2712443 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4712172 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4761203 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4759433 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL3561707 | 0.77 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| EP-2060570-B1 | Azabicyclo[3.1.0] hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1917013-B1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LTD (GB) | 2011-03-09 | — | — | EP | disclosed |
| US-7855298-B2 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| EP-2070922-A1 | Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-2060570-A2 | Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | Glaxo Group Limited (GB) | 2009-05-20 | — | — | EP | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1917013-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | SLC6A2 478/4885SLC6A4 415/4885SLC6A3 15/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | SLC6A2 894/4885SLC6A4 358/4885SLC6A3 30/4885 |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | SLC6A2 360/4885SLC6A4 395/4885SLC6A3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.